RVF Virus Replicon Particles for Safe Single-Dose Immunization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Rift Valley Fever virus (RVFV) lack efficacy and safety, particularly in livestock, with live attenuated vaccines posing risks of teratogenesis and abortion, and inactivated vaccines requiring multiple doses and adjuvants for complete protection.
Innovation Solution
Development of Rift Valley Fever virus replicon particles (VRPRVF) that are replication-competent but non-spreading, lacking the M genome segment encoding glycoproteins, allowing for a single round of infection and safe immunization without spread, thereby reducing vaccine-induced pathogenicity and enhancing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated vaccines are used to achieve high immunogenicity and single-dose protection, then immunogenicity is improved, but safety deteriorates due to risks of teratogenesis and abortion in livestock
Solution Approach 1:
The patent extracts the M genome segment encoding glycoproteins from the viral genome, creating a replication-competent but non-spreading virus. This allows the vaccine to replicate and induce strong immunity while preventing spread to other cells and causing pathogenicity. The extracted M segment is the key element responsible for both immunogenicity and harmful effects, and its removal resolves the contradiction.
Solution Approach 2:
The patent segments the viral genome into essential replication components (L and S segments) and non-essential spread components (M segment). By providing the M segment separately as a trans-complementary element, the vaccine achieves segmentation of function: replication capability without spread capability, resolving the contradiction between immunogenicity and safety.
2Object-affected harmful factors
If inactivated vaccines are used to ensure safety, then safety is improved, but immunogenicity deteriorates requiring multiple doses and adjuvants
Solution Approach 1:
The patent extracts only the harmful spread function (encoded by M segment) from the viral particle while retaining the replication function. This creates a vaccine that behaves like a live vaccine (replicating, highly immunogenic) but without the harmful spread capability, eliminating the need for adjuvants and multiple doses while ensuring safety.
Solution Approach 2:
The patent introduces a trans-complementary M segment as an intermediary element that mediates between the replication-competent viral particle and the host cell. This intermediary provides the necessary glycoproteins for immune recognition without enabling viral spread, resolving the contradiction between immunogenicity and safety.
3Reliability
If replication-competent viruses are used to enhance immunogenicity, then immunogenicity is improved, but safety deteriorates due to potential spread and pathogenicity
Solution Approach 1:
The patent extracts the M genome segment encoding glycoproteins from the viral particle genome. This extraction removes the capability for viral spread while preserving replication competence, as the extracted M segment is provided in trans-complementary form to support replication without enabling new particle formation and spread.
Solution Approach 2:
The patent applies local quality by making the viral replication competent only in the local context of the transfected cell, while preventing systemic spread. The M segment is provided locally in trans-complementary form, allowing replication in the infected cell but preventing the assembly and release of new infectious particles that would spread to other cells.
Data Source
AI summary
Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRPRVF) vaccine candidate. VRPRVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPRVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRPRVF, methods of producing VRPRVF, and method of using VRPRVF for immunization against RVF virus infection.